Circulating angiostatin, bFGF, and Tie2/TEK levels and their prognostic impact in bladder cancer

Urology

Volumn 80, Issue 3, 2012, Pages 737.e13-737.e18

  Szarvas, Tibor ^a,b   Jäger, Tobias ^a   Laszlo, Viktoria ^b   Kramer, Gero ^b   Klingler, H Christoph ^b   Vom Dorp, Frank ^a   Romics, Imre ^c   Ergün, Süleyman ^d   Rübben, Herbert ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c SEMMELWEIS UNIVERSITY   (Hungary)

^d UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN RECEPTOR; ANGIOSTATIN; FIBROBLAST GROWTH FACTOR 2;

AGED; ARTICLE; BLADDER CANCER; CANCER PROGNOSIS; CANCER SURVIVAL; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TRANSITIONAL CELL BLADDER CARCINOMA;

EID: 84865473503     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2012.03.023     Document Type: Article

References (30)

1. J.P. Stein, D.G. Skinner Radical cystectomy for invasive bladder cancer: long-term results of a standard procedure World J Urol 24 2006 296 304
2. N. Weidner, J.P. Semple, W.R. Welch Tumor angiogenesis and metastasis correlation in invasive breast carcinoma N Engl J Med 324 1991 1 8
3. M.S. O'Reilly, L. Holmgren, Y. Shing Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma Cell 79 1994 315 328
4. Y. Cao, N. Veitonmaki, K. Keough Elevated levels of urine angiostatin and plasminogen/plasmin in cancer patients Int J Mol Med 5 2000 547-351
5. C.D. Drenberg, B.O. Saunders, G.D. Wilbanks Urinary angiostatin levels are elevated in patients with epithelial ovarian cancer Gynecol Oncol 117 2010 117 124
6. H.J. Mauceri, S. Seetharam, M.A. Beckett Tumor production of angiostatin is enhanced after exposure to TNF-alpha Int J Cancer 97 2002 410 415
7. H. Yabushita, M. Noguchi, Y. Obayashi Angiostatin expression in ovarian cancer Oncol Rep 10 2003 1225 1230
8. M. Volm, J. Mattern, R. Koomgi Angiostatin expression in non-small cell lung cancer Clin Cancer Res 6 2000 3236 3240
9. M. Klagsbrun, M.A. Moses Molecular angiogenesis Chem Biol 6 1999 217 224
10. C. Dosquet, M.C. Coudert, E. Lepage Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma? Clin Cancer Res 3 1997 2451 2458
11. H. Joensuu, A. Anttonen, M. Eriksson Soluble syndecan-1 and serum basic fibroblast growth factor are new prognostic factors in lung cancer Cancer Res 62 2002 5210 5217
12. M.L. George, M.G. Tutton, A.M. Abulafi Plasma basic fibroblast growth factor levels in colorectal cancer: a clinically useful assay? Clin Exp Metastasis 19 2002 735 738
13. W.D. Beecken, T. Engl, J. Hofmann Clinical relevance of serum angiogenic activity in patients with transitional cell carcinoma of the bladder J Cell Mol Med 9 2005 655 661
14. C. Suri, P.F. Jones, S. Patan Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis Cell 87 1996 1171 1180
15. J. Holash, P.C. Maisonpierre, D. Compton Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF Science 284 1999 1994 1998
16. T. Szarvas, T. Jger, F. Droste Serum levels of angiogenic factors and their prognostic relevance in bladder cancer Pathol Oncol Res 15 2009 193 201
17. M.L. Wahl, T.L. Moser, S.V. Pizzo Angiostatin and anti-angiogenic therapy in human disease Recent Prog Horm Res 59 2004 73 104
18. Z. Huang, S.D. Bao Roles of main pro- and anti-angiogenic factors in tumor angiogenesis World J Gastroenterol 10 2004 463 470
19. S. Gately, P. Twardowski, M.S. Stack The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin Proc Natl Acad Sci U S A 94 1997 10868 10872
20. M.J. Duffy, T.M. Maguire, E.W. McDermott Urokinase plasminogen activator: a prognostic marker in multiple types of cancer J Surg Oncol 71 1999 130 135
21. M. Becker, T. Szarvas, M. Wittschier Prognostic impact of plasminogen activator inhibitor type 1 expression in bladder cancer Cancer 116 2010 4502 4512
22. P. Rutkowski, J. Kaminska, M. Kowalska Cytokine serum levels in soft tissue sarcoma patients: correlations with clinico-pathological features and prognosis Int J Cancer 100 2002 463 471
23. G. Sliutz, C. Tempfer, A. Obermair Serum evaluation of basic fibroblast growth factor in cervical cancer patients Cancer Lett 94 1995 227 231
24. J.I. Izawa, J.W. Slaton, D. Kedar Differential expression of progression-related genes in the evolution of superficial to invasive transitional cell carcinoma of the bladder Oncol Rep 8 2001 9 15
25. P. Gazzaniga, O. Gandini, A. Gradilone Detection of basic fibroblast growth factor mRNA in urinary bladder cancer: correlation with local relapses Int J Oncol 14 1999 1123 1127
26. M. De Palma, M.A. Venneri, R. Galli Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors Cancer Cell 8 2005 211 226
27. A.L. Harris, P. Reusch, B. Barleon Soluble Tie2 and Flt1 extracellular domains in serum of patients with renal cancer and response to antiangiogenic therapy Clin Cancer Res 7 2001 1992 1997
28. T. Szarvas, T. Jger, M. Ttsch Angiogenic switch of angiopietins-Tie2 system and its prognostic value in bladder cancer Clin Cancer Res 14 2008 8253 8262
29. L. Persano, M. Crescenzi, S. Indraccolo Anti-angiogenic gene therapy of cancer: current status and future prospects Mol Aspects Med 28 2007 87 114
30. M. De Palma, L. Naldini Tie2-expressing monocytes (TEMs): novel targets and vehicles of anticancer therapy? Biochim Biophys Acta 1796 2009 5 10